Skip to content
Head to head

Takeda Pharmaceutical vs Teva Pharmaceutical Industries

Side-by-side on the measures that matter, with a plain-English read. Full detail: TAK · TEVA

Updated 8 minutes ago

1-year performance, rebased to 100

TAK +56.6%TEVA +59.5%
Teva Pharmaceutical Industries edges it on the scoreable measures. Teva Pharmaceutical Industries has the highest Quant Rating (91); Teva Pharmaceutical Industries has done best over the past year (+62%); Teva Pharmaceutical Industries trades cheapest on trailing earnings.
TAKTEVA
Snapshot
Sector----
Last price21.7739.23
Change today+1.68%+1.79%
1-year return+57.5%+61.6%
Market cap$69.76B$45.77B
52-week range13.92 – 22.0724.34 – 44.57
Valuation
P/E (TTM)311.0091.23
P/E percentile, own 5-yr range100th99th
P/B1.505.74
Dividend yield1.44%0.00%
Profitability & growth
EPS (TTM)-0.301.21
Net profit (TTM)$-970.94M$1.41B
Revenue (TTM)$4.69T$17.23B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+6.7%-1.9%
Gross margin65.8%53.5%
Operating margin14.3%19.2%
Net margin0.9%2.9%
Free cash flow (TTM)$433.95B$1.23B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership51.3%79.4%
Insider activity (12mo)19 buy / 31 sell23 buy / 24 sell
Short interest (% of float)0.1%2.4%
Analyst consensus100% buy (1)100% buy (13)
Analyst price target$50 (+132%)$52 (+31%)
StockVane view
StockVane Quant RatingC (90)C (91)
Company
Employees47,02933,950
Founded17811901

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.